TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Reconsidering the place of BMT, BMT reporting consistency, and Q&A

Featured:

Alessandro M. VannucchiAlessandro M. VannucchiTiziano BarbuiTiziano BarbuiChloé JamesChloé JamesLaura MichaelisLaura MichaelisHaifa Kathrin Al-AliHaifa Kathrin Al-AliSteffen KoschmiederSteffen Koschmieder

Jul 29, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.


During the MPN Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the place of bone marrow transplant (BMT), and BMT reporting consistency. Alessandro Vannucchi delivered a presentation on use of BMT in myelofibrosis (MF), including strategies to optimize the outcomes of BMT and considerations to be made for special populations.

Reconsidering the place of bone marrow transplant (BMT), and BMT reporting consistency

Vannucchi discusses the increase trend for the use of allogenic hematopoietic stem cell transplant (allo-HSCT) in patients as well as the age of patients with MF who may be eligible. They highlight the importance of considering the risks and benefits of transplant, consideration comorbidities, and early transplant where possible. They also highlight how to optimize transplant outcomes, discussing the role of splenomegaly and management, as well as post-transplant monitoring. This presentation concludes with a discussion on the impact of TP53 mutations and accelerated vs blast phase MF in special populations.

Q&A

Following their presentation, Vannucchi chaired a Q&A session featuring Steering Committee members Laura Michaelis, Haifa Kathrin Al-Ali, Tiziano Barbui, Steffen Koschmieder, Chloe James, and guest speaker Benjamin Rolles. Discussions include how mutations, such as ASXL1, may impact selecting BMT and ruxolitinib in the first line, and how it could be used prior to BMT to prevent GvHD.

Reconsidering the place of BMT, and BMT reporting consistency: Q&A session

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content